Ruth M. Farrell, MD, MA, Marsha Michie, PhD, Christopher T. Scott, PhD, Rebecca Flyckt, MD, and Mary LaPlante, MD
One reason for neglect of women’s health as patients and subjects has been restrictions on uterine transfer of modified human embryos, a boundary that has now been crossed.
AMA J Ethics. 2019;21(12):E1071-1078. doi:
10.1001/amajethics.2019.1071.
How would gathering preclinical data and improving research infrastructure facilitate clearer definitions of “population vulnerability” and “risk acceptability”?
AMA J Ethics. 2020;22(1):E43-49. doi:
10.1001/amajethics.2020.43.
Aminu Yakubu, Nchangwi Syntia Munung, and Jantina De Vries, PhD
African cancer research is embedded in underresourced health care infrastructures, illuminating ethical questions about benefit sharing and governance.
AMA J Ethics. 2020;22(2):E156-163. doi:
10.1001/amajethics.2020.156.
This commentary on a case considers a transgender patient’s mental health and risk for DVT in ethical decision making about feminizing gender-affirming hormone therapy.
AMA J Ethics. 2023;25(6):E386-390. doi:
10.1001/amajethics.2023.386.
Lee C. Zhao, MD, Gaines Blasdel, Augustus Parker, and Rachel Bluebond-Langner, MD
Tension between realistic goals and unrealistic views about how to achieve them is compounded when patients are eager to revise a prior surgeon’s gender-affirming procedure.
AMA J Ethics. 2023;25(6):E391-397. doi:
10.1001/amajethics.2023.391.